Drugs / BMS-986148
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02884726 | Oct 2016 → Sep 2017 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02341625 | Jun 2015 → Feb 2019 | — | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986148 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02884726 ↗ |
| Known as | BMS-986148-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068574 ↗ |
| Route | Intravenous | “BMS-986148 monotherapy (0.1-1.6 mg/kg intravenously (i.v.) every 3 weeks” PMID 34615718 ↗ Oct 2021 |
| Target | MSLN | “a mesothelin-directed antibody-drug conjugate (ADC)” PMID 34615718 ↗ Oct 2021 |